Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3711795 | 1.00 | RAB9A (0.34) | RAB9AKDM4ENPC1SMN1; SMN2THRB | |
| SCHEMBL10989953 | 0.83 | TOP2A (0.37) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL8412572 | 0.83 | TOP2A (0.37) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL15193068 | 0.83 | TOP2A (0.37) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL13614213 | 0.81 | RAB9A (0.38) | RAB9AKDM4ENPC1SMN1; SMN2THRB | |
| SCHEMBL16976870 | 0.80 | RAB9A (0.38) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL16976823 | 0.80 | RAB9A (0.38) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL12035124 | 0.78 | RAB9A (0.38) | RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL441609 | 0.76 | RAB9A (0.37) | RAB9AKDM4ENPC1SMN1; SMN2THRB | |
| SCHEMBL13531627 | 0.76 | RAB9A (0.34) | RAB9AKDM4ENPC1SMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382272-B2 | Methods of making lubiprostone and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2016-07-05 | — | — | US | disclosed |
| US-8785663-B2 | Polymorphic forms of Lubiprostone | APOTEX PHARMACHEM INC. (CA) | 2014-07-22 | — | — | US | disclosed |
| US-8785663-B2 | Polymorphic forms of Lubiprostone | APOTEX PHARMACHEM INC. (CA) | 2014-07-22 | — | — | US | disclosed |
| US-20130096325-A1 | POLYMORPHIC FORMS OF LUBIPROSTONE | APOTEX PHARMACHEM INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| US-20130096325-A1 | POLYMORPHIC FORMS OF LUBIPROSTONE | APOTEX PHARMACHEM INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| US-20120065409-A1 | METHODS OF MAKING LUBIPROSTONE AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096325-A1 | POLYMORPHIC FORMS OF LUBIPROSTONE | APOB, OSBP2, LDLR | RAB9A 4467/4885KDM4E 4687/4885NPC1 260/4885 |
| US-20120065409-A1 | METHODS OF MAKING LUBIPROSTONE AND INTERMEDIATES THEREOF | PTGIS, LSS, SQLE | RAB9A 3902/4885KDM4E 3835/4885NPC1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.